My Top 3 Biotech Stocks for May 2026
As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies are beginning to stand out from the crowd.
SRPT - Sarepta Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$24.50
DETAILS
HIGH:
$35.00
LOW:
$14.00
MEDIAN:
$23.50
CONSENSUS:
$24.50
UPSIDE:
45.83%
Stock News
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference at the InterContinental New York Barclay on Wednesday, May 20, at 8:30 a.m. ET. The presentations will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presen.
Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained
SRPT beats Q1 earnings and revenue estimates despite a sharp Elevidys sales drop, while maintaining its 2026 product revenue outlook.
Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript
Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript
Sarepta Therapeutics (SRPT) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates
Sarepta Therapeutics (SRPT) came out with quarterly earnings of $3.16 per share, beating the Zacks Consensus Estimate of $0.9 per share. This compares to a loss of $3.42 per share a year ago.
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2026. "We entered 2026 with clear priorities—stabilizing the business, restoring growth, maintaining financial strength, and advancing a pipeline that we believe can define Sarepta's next era. In the first quarter, we made meaningful progress against each,” said Doug Ingram, chief executive officer, Sarept.
Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth
Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, May 6, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss these results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentation.
Aberdeen Group plc Increases Stake in Sarepta Therapeutics, Inc. $SRPT
Aberdeen Group plc increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 13.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,251,593 shares of the biotechnology company's stock after purchasing an additional 268,829 shares during the
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 31, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 24 individuals hired by Sarepta in the first quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rule.
MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI's 2026 Performance
SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size.
Why Is Sarepta Therapeutics (SRPT) Up 24.2% Since Last Earnings Report?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
SRPT Stock Surges on Promising Early Results From siRNA Programs
Sarepta Therapeutics shares surge 35% as early data from two siRNA therapies show strong target knockdown, safety and muscle delivery potential.
Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?
Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Sarepta Therapeutics Target of Unusually Large Options Trading (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. (NASDAQ: SRPT - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Investors acquired 6,110 call options on the company. This is an increase of approximately 44% compared to the typical daily volume of 4,234 call options. Insider Activity In related news, Director Stephen Mayo sold 7,239 shares
Sarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1 Transcript
Sarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1 Transcript
Sarepta Therapeutics' experimental siRNA therapies show promising early results
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares surged almost 26% to about $22 after the biotechnology company shared early clinical results from two of its investigational siRNA therapies for neuromuscular diseases, showing dose-dependent muscle exposure and favorable tolerability. Phase 1/2 studies of SRP-1001 for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and SRP-1003 for myotonic dystrophy type 1 (DM1) demonstrated that the αvβ6 integrin-targeted delivery platform achieved high concentrations in muscle tissue without dose-limiting toxicity.
Why Is Sarepta Therapeutics Stock Exploding Today?
Sarepta Therapeutics recently shared the first clinical results from its siRNA programs, specifically SRP-1001 and SRP-1003, which are designed to treat facioscapulohumeral muscular dystrophy (FSHD1) and myotonic dystrophy type 1 (DM1), respectively.
Price Targets
Sarepta price target lowered to $19 from $20 at Evercore ISI
$19.00
(was $18.20)
Evercore ISI
Deutsche ups Sarepta target, says 35% stock rally overdone
$14.00
(was $21.68)
Deutsche Bank
Sarepta price target raised to $35 from $29 at Wedbush
$35.00
(was $21.68)
Wedbush
Sarepta Therapeutics (SRPT) PT Raised to $31 at Mizuho
$31.00
(was $17.04)
Uy Ear
·
Mizuho Securities
Sarepta Therapeutics (SRPT) PT Raised to $25 at Freedom Capital Markets
$25.00
(was $15.87)
Ilya Zubkov
·
Loop Capital Markets
Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT); cites as potential "recovery story"
$30.00
(was $15.98)
Andrew Tsai
·
Jefferies
Sarepta price target raised to $22 from $15 at Baird
$22.00
(was $22.80)
Robert W. Baird
Wedbush bullish on Sarepta, initiates with an Outperform
$32.00
(was $21.86)
Wedbush
Sarepta price target raised to $20 from $18 at Bernstein
$20.00
(was $18.91)
Bernstein
Sarepta price target lowered to $20 from $22 at Barclays
$20.00
(was $16.20)
Barclays
Mizuho Upgrades Sarepta Therapeutics (SRPT) to Outperform
$26.00
(was $16.20)
Uy Ear
·
Mizuho Securities
Sarepta Therapeutics (SRPT) PT Lowered to $15 at Baird
$15.00
(was $24.45)
Brian Skorney
·
Robert W. Baird
Sarepta price target raised to $16 from $15 at Piper Sandler
$16.00
(was $23.45)
Biren Amin
·
Piper Sandler
Sarepta price target raised to $15 from $12 at Leerink
$15.00
(was $17.57)
Joseph Schwartz
·
Leerink Partners
Sarepta debt refinancing eases liquidity concerns, says Barclays
$22.00
(was $20.06)
Barclays
Sarepta price target raised to $12 from $6 at Deutsche Bank
$12.00
(was $20.30)
David Hoang
·
Deutsche Bank
Barclays Downgrades Sarepta Therapeutics (SRPT) to Equalweight
$18.00
(was $13.32)
Gena Wang
·
Barclays
BMO Capital Reiterates Market Perform Rating on Sarepta Therapeutics (SRPT)
$50.00
(was $14.07)
Kostas Biliouris
·
BMO Capital
Sarepta downgraded to Market Perform from Outperform at Leerink
$10.00
(was $14.07)
Joseph Schwartz
·
Leerink Partners
Sarepta has little value if Elevidys withdrawn, says H.C. Wainwright
$10.00
(was $17.46)
H.C. Wainwright